Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial

To the Editor:
Multiple myeloma (MM) is associated with a high burden of disease, compromising patients' health‐related quality of life (HRQOL). With improvements in overall survival, HRQOL has become an increasingly important outcome. Patient‐reported outcome measures (PROMs) are tools that collect patient‐reported outcomes (PROs) ‐ an individual's evaluation of their own health and wellbeing ‐ and incorporate HRQOL. Routine monitoring of symptoms and other PROs to inform cancer care has been shown to improve patient outcomes including HRQOL1, 2 in solid tumors. However, few data exist for hematological malignancies,3, 4 and even fewer for MM.4 To design a randomized controlled trial (RCT) to assess the impact of real‐time feedback of PROs, feasibility and acceptability to patients and clinicians of such an intervention needed evaluation. To achieve this, we designed the My‐PROMPT pilot RCT to determine feasibility and appropriateness of study design, including acceptability to patients and clinicians; and to understand any change in HRQOL over time, in order to inform sample size calculation for a future trial.